Form 4: Phathom Pharmaceuticals Officer Reports Future Stock Sale for Tax Obligations
Insider Transaction Report
Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, has filed a Form 4 indicating a future sale of 1,692 shares of common stock on July 16, 2025, to cover tax withholding obligations from restricted stock unit settlements.
Summary
- Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc. (PHAT), reported a planned sale of 1,692 shares of common stock.
- The transaction is scheduled for July 16, 2025, at a weighted average price of $8.3639 per share.
- The sale is specifically to satisfy tax withholding obligations arising from the settlement of restricted stock units.
- The shares were sold in multiple transactions at prices ranging from $8.35 to $8.364.
- Following this transaction, Mr. Breedlove will directly own 48,392 shares of common stock and indirectly own 5,108.4 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine 'sell to cover' for tax purposes, not indicative of a discretionary sale based on the officer's view of the company's prospects.
Future Outlook
The filing indicates a pre-planned transaction under Rule 10b5-1(c) for a future date, specifically to cover tax obligations, which is a routine event for equity compensation settlements.
Industry Context
This Form 4 filing is a routine disclosure of an insider stock transaction, common in the pharmaceutical industry and across publicly traded companies, particularly when executives receive equity compensation that triggers tax liabilities upon vesting or settlement.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not signaling a change in management's confidence.
- Employees: No direct impact.
Key Dates
| Date | Description |
|---|---|
| 07/16/2025 | Date of planned common stock transaction by Robert Charles Breedlove. |
| 07/18/2025 | Date the Form 4 was filed with the SEC. |
Keywords
Phathom Pharmaceuticals, PHAT, SEC Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Corporate Officer, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.